human
immunodefici
viru
hiv
infect
pose
global
challeng
given
accord
world
health
organ
data
million
peopl
live
hiv
addit
million
peopl
becom
newli
infect
global
tabl
hiv
target
immun
cell
impair
human
defens
pneumonia
tuberculosi
shingl
well
certain
type
cancer
advanc
stage
hiv
infect
acquir
immunodefici
syndrom
aid
take
two
year
develop
depend
individu
hiv
two
viral
form
common
form
account
around
infect
worldwid
rel
uncommon
less
infecti
consist
group
n
p
least
nine
genet
distinct
subtyp
within
group
b
c
f
g
h
j
k
addit
differ
subtyp
combin
genet
materi
form
hybrid
viru
known
circul
recombin
form
crf
figur
consist
eight
known
group
h
group
b
pandem
mechan
clearli
defin
neither
differ
howev
transmiss
rate
much
lower
estim
genet
distinct
genom
read
frame
code
structur
regulatori
protein
gag
gene
encod
precursor
inner
structur
protein
capsid
protein
ca
matrix
protein
nucleoprotein
nc
involv
viru
particl
releas
pol
gene
encod
precursor
viral
enzym
proteas
pr
revers
transcriptas
rt
rnase
h
integras
env
gene
encod
precursor
surfac
glycoprotein
su
transmembran
protein
tm
gene
includ
tat
encod
transactiv
protein
rev
encod
rna
splice
regul
nef
encod
neg
regul
factor
vif
encod
viral
infect
protein
vpr
encod
viru
protein
r
vpu
encod
viru
protein
uniqu
vpx
encod
viru
protein
x
tev
encod
tatrev
protein
hiv
infect
extrem
problemat
viru
target
memori
tcell
popul
essenti
organ
immun
hiv
attach
host
cell
rel
nonspecif
interact
neg
charg
cellsurfac
heparan
sulfat
proteoglycan
specif
interact
env
integrin
andor
interact
patternrecognit
receptor
dendrit
cellspecif
intercellular
adhes
molecular
nonintegrin
dcsign
attach
hiv
abovement
way
increas
efficaci
infect
bring
env
heavili
glycosyl
trimer
heterodim
close
proxim
viral
receptor
coreceptor
final
order
viral
entri
occur
env
need
bind
host
protein
bind
hiv
glycoprotein
host
cell
receptor
caus
conform
chang
glycoprotein
uncov
addit
bind
site
interact
distinct
protein
host
cell
membran
known
coreceptor
mainli
facilit
viru
entri
cell
infect
progress
declin
cell
consequ
lead
failur
immun
system
function
develop
opportunist
infect
usual
lead
death
hivinfect
patient
immunodefici
develop
result
viral
replic
failur
patient
homeostat
mechan
continu
viral
presenc
patient
applic
therapi
attribut
tcell
homeostasi
owe
pool
latent
infect
rest
tcell
macrophag
follicular
dendrit
cell
remain
organ
inde
complex
interact
patient
immun
system
viru
vice
versa
viral
suppress
thought
crucial
control
diseas
progress
current
therapeut
approach
mainli
target
protein
vital
viral
cycl
one
promin
exampl
linear
acid
synthet
peptid
enfuviritid
fuzeon
develop
hoffmannla
roch
first
fda
approv
fusion
inhibitor
treatment
act
bind
subunit
envelop
glycoprotein
induc
conform
chang
bring
viral
cellular
membran
close
enough
proxim
fusion
subsequ
viral
entri
hostcel
occur
nevertheless
sever
restrict
low
genet
barrier
drug
resist
short
vivo
halflif
limit
clinic
use
variou
fdaapprov
antiretrovir
drug
seven
mechanist
class
inhibitor
hiv
replic
also
avail
treatment
infect
patient
name
nucleosid
reversetranscriptas
inhibitor
nrti
nonnucleosid
reversetranscriptas
rt
inhibitor
nnrti
protein
inhibitor
pi
fusion
inhibitor
entri
coreceptor
antagonist
hiv
integras
strand
transfer
inhibitor
multiclass
combin
none
mention
drug
class
alon
combin
latter
known
highli
activ
antiretrovir
therapi
haart
erad
hiv
infect
effect
vaccin
remain
unavail
difficulti
vaccin
research
part
result
unavail
model
natur
immun
relat
hiv
exist
genet
distinct
subtyp
hiv
frequent
mutat
unidentifi
correl
specif
immun
respons
hiv
lack
reliabl
nonhuman
anim
model
hiv
infect
siv
monkey
vs
hiv
human
establish
latent
provir
reservoir
patient
bodi
stochast
begin
reproduc
viral
particl
make
hiv
diseas
practic
incur
compound
identifi
far
latencyrevers
agent
lra
none
led
promis
cure
sever
rare
longterm
remiss
hiv
case
describ
literatur
exampl
berlin
london
patient
underw
bone
marrow
transplant
stem
cell
donor
rare
genet
mutat
mississippi
babi
receiv
earli
antiretrovir
therapi
extend
time
viral
rebound
month
undoubtedli
remain
lot
learn
case
investig
stemcel
transplant
peopl
live
hiv
requir
current
use
antiretrovir
treatment
alon
combin
extend
qualiti
life
expect
hivinfect
individu
cure
drug
resist
along
emerg
drugresist
viru
strain
highcost
lifetim
treatment
regimen
cell
toxic
seriou
side
effect
current
use
antihiv
drug
underli
need
synthet
develop
new
drug
search
activ
antihiv
molecul
natur
sourc
mother
natur
perfect
chemistri
three
billion
year
done
water
intens
competit
feed
pressur
well
nonstat
marin
environment
condit
yield
compound
chemic
structur
featur
gener
found
terrestri
natur
product
new
effici
molecul
direct
hiv
demonstr
better
perform
comparison
current
approv
drug
suppress
hiv
viru
andor
elimin
latent
hiv
reservoir
present
human
bodi
around
drug
current
avail
market
deriv
inspir
natur
turn
natur
drug
develop
hold
great
potenti
especi
come
marin
organ
marinederiv
drug
approv
market
far
mani
preclin
clinic
stage
develop
marin
organ
make
twothird
earth
speci
produc
consequ
live
highli
competit
environ
uniqu
structur
divers
metabolit
last
year
bioprospect
effort
result
compound
marin
origin
highest
share
marin
metabolit
obtain
marin
spong
coral
microorgan
mollusk
ascidian
alga
metabolit
form
minor
part
ocean
inde
still
rather
underexploit
habitat
biodivers
appear
higher
ocean
land
might
relev
focus
marin
environ
untap
reservoir
novel
antiretrovir
candid
discoveri
new
antivir
marinederiv
drug
research
usual
implement
two
strategi
either
screen
extract
differ
strain
eg
cyanobacteria
microalga
search
directli
bioactiv
molecul
purifi
evalu
within
drug
develop
pipelin
thought
marin
environ
might
yield
potent
antihiv
candid
character
higher
effici
lower
effect
dose
better
select
induc
resist
develop
could
cours
specul
base
previou
success
stori
discoveri
drug
natur
sourc
eg
lovastatin
paclitaxel
howev
natur
gener
creat
sophist
perfect
system
complex
mode
action
excel
exampl
protein
lectin
deriv
marin
red
alga
griffithsia
sp
name
griffithsin
midpicomolar
activ
group
among
potent
hiv
entri
inhibitor
report
far
inhibit
hiv
infect
bind
high
mannos
glycan
structur
surfac
alter
structur
oligomer
state
interact
reli
specif
trimer
sugar
tower
includ
griffitshin
also
prevent
infect
caus
glycoproteinenvelop
virus
ebola
viru
hepat
c
viru
sever
acut
respiratori
syndrom
coronaviru
shown
dimer
griffithsin
necessari
high
potenc
inhibit
howev
discrep
hiv
bind
activ
hiv
inhibitori
activ
point
presenc
mechan
unrel
mere
simpl
hiv
bind
promis
applic
griffithsin
would
incorpor
vagin
rectal
gel
cream
suppositori
act
antivir
microbicid
prevent
transmiss
hiv
despit
vast
number
structur
divers
uniqu
bioactiv
molecul
marin
environ
global
marin
pharmaceut
pipelin
includ
eight
approv
drug
overal
taken
year
discoveri
entri
market
sustain
suppli
structur
complex
optim
formul
admet
properti
scaleup
issu
prevent
develop
sever
highli
promis
marin
compound
mean
easi
task
identifi
marin
candid
may
consid
potenti
drug
initi
high
cost
develop
natur
product
drug
could
balanc
care
longterm
consider
biodivers
suppli
technic
market
paper
provid
overview
natur
marin
metabolit
first
identifi
period
previous
identifi
marin
constitu
recent
confirm
antihiv
activ
could
potenti
use
optim
novel
anthiv
agent
also
comprehens
summar
antihiv
activ
sever
categori
marin
structur
includ
chitosan
deriv
sulfat
polysaccharid
lectin
bromotyrosin
deriv
peptid
alkaloid
diterpen
phlorotannin
xanthon
well
fish
oil
auxiliari
haart
therapi
chitosan
figur
natur
marin
byproduct
polycation
linear
polysaccharid
deriv
chitin
figur
partial
deacetyl
chitin
structur
element
exoskeleton
mainli
shrimp
crab
mainli
compos
randomli
distribut
link
dglucosamin
nacetyldglucosamin
previous
shown
compound
exhibit
larg
scale
differ
bioactiv
also
use
carrier
antihiv
drug
chitosan
load
saquinavir
antihiv
drug
proteas
inhibitori
activ
show
better
cell
target
effici
saquinavir
alon
furthermor
trimethyl
chitosan
improv
atripla
antihiv
drug
consist
efavirenz
emtricitabin
tenofovir
disoproxil
fumar
antihiv
activ
allow
use
lower
concentr
antiretrovir
activ
manifest
chitosanspecif
cation
natur
allow
format
electrostat
complex
multilay
structur
neg
charg
polym
karagozlu
et
al
report
new
qmwco
wmqco
oligom
antihiv
activ
oligom
conjug
chitosan
glnmettrp
peptid
construct
continu
author
previou
research
high
potenc
synthet
construct
chitosan
oligom
confirm
antihiv
therapi
specif
shown
oligom
suppress
syncytium
format
occur
fusion
infect
cell
neighbor
cell
induc
hiv
dosedepend
manner
howev
author
also
notic
certain
period
number
syncytia
increas
suggest
cell
retreat
qmwco
wmqco
oligom
maintain
primari
therapeuticallyrelev
effect
inhibit
induc
lytic
effect
determin
cell
viabil
assay
show
qmwco
almost
ident
wmqco
oligom
effect
reduc
hiv
load
show
effect
rt
proteas
vitro
higher
dosag
also
requir
reduct
antigen
product
assess
elisa
assay
antigen
product
highest
differ
compound
reflect
valu
obtain
studi
virusinduc
luciferas
activ
infect
cell
qmwco
higher
potenc
comparison
wmqco
lastli
author
determin
effect
oligom
interact
use
elisa
assay
wherebi
oligom
show
high
potenc
effect
oligom
highest
appli
immedi
upon
infect
cell
indic
use
potenti
treatment
earli
stage
hiv
infect
probabl
entri
stage
heparinoid
polysaccharid
interact
positivecharg
region
cellsurfac
glycoprotein
lead
shield
effect
region
prevent
bind
virus
cell
surfac
sulfat
polysaccharid
content
marin
mollusk
high
comparison
bovin
mucos
heparin
porcin
mucos
heparin
acid
sulfat
group
heparin
figur
heparinlik
compound
inhibit
hiv
electrostat
interact
basic
aminoacid
residu
transcript
activ
tat
protein
far
main
antiinfecti
activ
document
fucosecontain
sp
virus
importantli
polysaccharid
select
inhibitor
variou
envelop
virus
includ
hiv
fcsp
act
earli
phase
infect
block
viru
attach
entri
host
cell
may
also
inhibit
subsequ
replic
stage
vitro
three
fucoidan
extract
three
brown
seawe
sargassum
mcclurei
sargassum
polycystum
turbinara
ornata
inhibit
earli
stage
entri
target
cell
rang
neither
sulfat
content
posit
sulfat
group
relat
antihiv
activ
fucoidan
suggest
involv
structur
paramet
molecular
weight
type
glycosid
linkag
even
uniqu
fucoidan
sequenc
although
presenc
sulfogroup
seem
necessari
antihiv
activ
data
support
random
sulfat
main
antivir
factor
sulfat
fucan
polysaccharid
ascophyllan
figur
two
fucoidan
tabl
deriv
differ
sourc
significantli
inhibit
earli
step
jrfl
infect
also
inhibit
vsvgpseudotyp
infect
hela
cell
chondroitin
sulfat
fucosyl
branch
fuc
figur
also
attract
attent
hiv
antivir
compound
depolymer
fucosyl
cs
extract
sea
cucumb
shown
vitro
activ
rang
viral
strain
includ
resist
one
fuc
effect
block
laboratori
strain
entri
replic
inhibit
antigen
product
respect
infect
clinic
isol
respect
well
suppress
drugresist
viru
addit
fuc
also
effect
strain
valu
rang
depolymer
fragment
seem
maintain
similar
antihiv
action
earli
stage
infect
appar
interact
hiv
envelop
glycoprotein
sulfat
fucos
branch
appear
necessari
antivir
activ
also
affect
molecular
weight
carboxyl
vitro
result
fucosyl
cs
hiv
promis
question
whether
antivir
activ
would
maintain
vivo
polyanion
hiv
entri
inhibitor
advanc
clinic
trial
fail
prove
effect
heterosexu
transmiss
relat
factor
consid
previou
develop
stage
presenc
semin
plasma
concentr
retent
polyanion
inhibitor
complex
chemic
architectur
sulfat
pattern
marin
polysaccharid
depend
numer
factor
speci
tidal
cycl
environment
variat
eg
salin
harvest
season
plant
age
geograph
locat
etc
make
isol
purif
comprehens
chemic
character
highli
challeng
task
develop
mani
polysaccharid
clinic
applic
hinder
still
limit
view
sophist
divers
natur
despit
good
antivir
effect
use
carbohydr
drug
still
infanc
intens
structureact
vivo
studi
need
futur
rel
new
strategi
induc
immun
develop
hiv
vaccin
use
carbohydr
major
difficulti
approach
lie
mimick
specif
glycan
protect
epitop
hiv
highli
glycosyl
envelop
surfac
glycoprotein
respons
receptor
coreceptor
bind
togeth
compris
heterodimer
envelop
trimer
spike
hiv
nlink
glycan
mainli
mannos
complextyp
cover
much
surfaceaccess
face
hiv
envelop
spike
form
glycan
shield
inadequ
mimicri
glycan
shield
toler
mechan
andor
inabl
induc
domainexchang
reflect
difficulti
creat
proper
specif
ab
vaccin
preclin
trial
base
oligomannosyl
epitop
variou
conjug
engin
yeast
strain
modifi
glycoprotein
better
specif
could
potenti
gain
use
carbohydr
marin
origin
lectin
group
protein
specif
revers
bind
glycosyl
molecul
cell
surfac
precis
group
molecul
affect
cellcel
interact
protect
cell
pathogen
influenc
cell
adhes
affect
intracellular
glycoprotein
transloc
recent
lectin
becom
promis
agent
antiretrovir
therapi
differ
research
confirm
antihiv
properti
antiretrovir
activ
manifest
alter
interact
hiv
correspond
receptor
end
inhibit
hiv
cell
function
hiv
infect
format
syncytium
multinucl
cell
sever
publish
review
paper
describ
previous
found
marin
lectin
antiretrovir
action
exampl
gogineni
et
al
report
new
unusu
lectin
specif
lectin
cvl
cgl
dtl
dtla
addit
akkouh
et
al
report
new
algal
lectin
boodlea
coacta
lectin
griffithsin
oscillatoria
agardhii
agglutinin
oaa
cyanobacteri
lectin
cyanovirinn
scytovirin
microcysti
viridi
lectin
microvirin
howev
last
year
much
research
focus
antihiv
lectin
marin
sourc
hirayama
et
al
report
new
highmannos
specif
lectin
recombin
possess
antihiv
activ
research
perform
red
alga
kappaphycu
alvarezii
author
confirm
two
kaa
mannosebind
lectin
isom
potent
antihiv
agent
antihiv
role
action
two
compound
includ
strong
bind
viru
envelop
glycoprotein
consequ
inhibit
hiv
entri
host
cell
kaa
recombin
well
nativ
one
inhibit
entri
neutral
assay
jurkat
cell
nm
author
conclud
end
kaa
besid
strong
inhibitori
effect
hiv
entri
cell
potenti
agent
treatment
virus
possess
high
mannos
glycan
envelop
well
shown
major
marin
peptid
strong
antihiv
activ
usual
isol
marin
organ
process
enzymat
hydrolysi
common
sourc
constitu
marin
spong
known
uniqu
metabolom
sourc
marin
bioactiv
compound
bioactiv
peptid
found
cyclic
linear
form
contain
unusu
amino
acid
form
uniqu
structur
rare
found
speci
antiretrovir
activ
structur
work
sever
differ
level
block
viru
entri
inhibit
cytopath
viral
activ
neutral
viral
particl
inhibit
viral
fusion
entri
recent
shin
et
al
discov
two
new
depsipeptid
marin
spong
stelletta
sp
stellettapeptin
figur
stellettapeptin
b
figur
inhibit
cytopath
effect
infect
confirm
mention
theori
uniqu
metabolom
marin
spong
author
reveal
two
compound
previous
undescrib
nonproteinogen
aminoacid
part
peptid
rare
found
natur
name
stellettapeptin
stellettapeptin
b
unexpect
polyketid
subunit
acid
residu
high
potenc
wit
low
valu
inhibit
cytotox
effect
upon
hiv
infect
nm
stellettapeptin
nm
stellettapeptin
b
furthermor
newli
discov
antihiv
constitu
deriv
marin
spong
verongula
rigida
aiolochoria
crassa
aminoacid
structur
publish
gomezarchila
et
al
paper
evalu
confirm
antihiv
effect
bromotyrosin
deriv
tabl
wherebi
purealidin
b
fistularin
figur
potent
antihiv
activ
aeroplysinin
purealidin
b
compound
found
v
rigida
speci
inhibit
replic
dosedepend
manner
specif
aeroplysinin
hiva
replic
inhibit
concentr
wherea
purealidin
less
potent
inhibitori
power
concentr
two
compound
previous
isol
howev
antihiv
activ
proven
research
rel
high
percentag
inhibit
hiv
activ
dosedepend
manner
howev
exact
mechan
action
remain
unclear
studi
addit
test
compound
hiv
rt
inhibit
qpcr
earli
late
transcript
nuclear
import
qpcr
analysi
transcript
hiv
entri
inhibit
viral
infect
assay
perform
result
show
purealidin
b
fistularin
influenc
nuclear
import
hiv
viru
around
inhibit
show
inhibit
inhibit
purealidin
b
inhibit
fistularin
inhibit
inhibit
viral
rt
inhibit
high
compound
wherebi
highest
result
around
inhibit
exampl
purealidin
b
inhibit
qpcr
analysi
earli
transcript
hiv
entri
inhibit
compound
activ
dosedepend
manner
highest
result
inhibit
obtain
n
n
otetramethyltyraminium
final
author
stress
structur
similar
compound
hiv
integras
proteas
inhibitor
suggest
compound
broader
mode
antivir
action
marin
spong
sole
sourc
bioactiv
protein
exampl
jang
et
al
report
new
small
hydroxyprolinerich
peptid
alaska
pollack
collagen
aphcp
figur
exhibit
uniqu
antivir
activ
peptid
glyprohypglyprohypglyprohypgli
peptid
author
show
import
part
peptid
antihiv
activ
hydroxyl
group
hydroxyprolin
wherea
peptid
prolin
exhibit
antivir
activ
antihiv
mode
action
manifest
inhibit
induc
syncytia
format
interfer
hiv
fusion
inhibit
cell
lysi
rt
activ
product
antigen
shown
aphcp
decreas
induc
cell
lysi
potenc
around
induc
cell
assay
addit
inhibit
viral
rt
peptid
crucial
role
inhibit
convers
viral
rna
dna
also
confirm
compound
effect
suppress
product
viral
cell
determin
western
blot
analysi
similarli
one
new
antihiv
peptid
isol
spirulina
maxima
smpeptid
leuaspalavalasnarg
peptid
author
show
infect
inhibit
human
cell
line
peptid
inhibit
cell
lysi
antigen
product
rt
specif
obtain
cell
viabil
assay
antihiv
infect
determin
mm
inhibit
rt
activ
rt
assay
kit
cell
high
concentr
mm
product
antigen
product
assay
inhibit
concentr
mm
marin
organ
wellestablish
sourc
natur
alkaloid
although
term
alkaloid
seem
puzzl
prone
scientif
controversi
alkaloid
gener
defin
nitrogencontain
compound
deriv
plant
anim
rel
alkaloid
marin
sourc
found
possess
antiretrovir
properti
far
none
found
clinic
use
aspernigrin
c
figur
malformin
c
figur
isol
marinederiv
black
aspergili
aspergillu
niger
scsio
inhibitori
activ
chemokin
receptor
subtyp
tropic
evalu
show
potent
inhibit
infect
valu
compar
nucleosid
revers
transcriptas
entri
inhibitor
comparison
aspernigrin
suggest
moieti
respons
potenc
aspernigrin
c
thiodiketopiperazinetyp
alkaloid
eutypellazin
isol
etoac
extract
ferment
broth
deepsea
sediment
fungu
eutypella
sp
show
potent
inhibitori
effect
cotransfect
hiv
model
cell
eutypellazin
e
figur
exert
activ
low
micromolar
rang
eutypellazin
j
figur
show
reactiv
effect
toward
latent
jlat
cell
could
use
promis
strategi
expung
infect
activ
latent
viru
cellular
reservoir
combin
haart
carteri
red
sea
spong
extract
yield
three
previous
character
compound
debromohymenialdisin
dbh
figur
hymenialdisin
hd
figur
oroidin
figur
dbh
hd
exhibit
inhibit
associ
cytotox
convers
oroidin
display
inhibit
viral
replic
without
observ
cytotox
also
show
inhibit
revers
transcriptas
two
known
alkaloid
aaptamin
famili
contain
de
skeleton
name
phenetylamino
demethyl
oxi
aaptamin
figur
isopentylamino
demethyl
oxi
aaptamin
figur
isol
spong
apto
exhibit
antihiv
activ
inhibitori
rate
respect
concentr
bengamid
figur
haliclonycyclamin
ab
figur
keramamin
c
figur
inhibit
effect
concentr
less
potent
among
bengamid
block
cell
line
compar
control
antiretrovir
indinavir
efavirenz
raltegravir
peripher
blood
mononuclear
cell
conclud
ltr
respons
element
requir
bengamid
amedi
inhibit
ltrdepend
gene
express
phenylspirodriman
stachybotrin
figur
isol
spongederiv
fungu
stachybotri
chartarum
discov
rt
inhibitor
show
inhibitori
effect
wild
type
five
nnrtiresist
strain
mani
terpen
marin
natur
product
demonstr
antihiv
properti
mechan
action
involv
block
differ
step
replic
cycl
revers
transcriptas
inhibitor
proteas
inhibitor
entri
inhibitor
among
diterpen
marin
alga
nowaday
spotlight
due
promis
antihiv
activ
dolabellan
diterpen
compound
diterpen
group
recent
extens
studi
antihiv
activ
pardovarga
et
al
character
three
new
dolabellan
diterpen
isol
marin
brown
alga
dictyota
pfaffii
northeast
brazil
dolabelladien
dolabelladien
name
dolabelladienol
figur
respect
particular
new
compound
dolabelladienol
b
show
potent
activ
confirm
low
valu
low
cytotox
activ
lymphocyt
tumor
cell
promis
agent
even
activ
previous
known
seri
de
souza
barro
et
al
test
marin
dolastan
figur
secodolastan
diterpen
figur
isol
brown
alga
canistrocarpu
cervicorni
activ
observ
marin
diterpen
inhibit
replic
dosedepend
manner
valu
without
cytotox
effect
valu
rang
addit
investig
virucid
effect
diterpen
potenti
use
microbicid
dolastanediterpen
show
potent
effect
infect
wherea
virucid
effect
observ
secodolastan
diterpen
demonstr
anoth
mechan
antiretrovir
activ
therefor
author
suggest
potenti
use
marin
dolastan
microbicid
could
directli
inhibit
viru
infect
possibl
act
viru
penetr
target
cell
dolabelladienetriol
brown
alga
dictyota
spp
also
evalu
potenti
microbicid
tissu
explant
name
stephen
et
al
examin
figur
pretreat
peripher
blood
cell
pbmc
macrophag
along
protect
effect
ex
vivo
explant
model
uterin
cervix
pretreat
peripher
pbmc
macrophag
dolabelladienotriol
show
inhibitori
effect
replic
furthermor
explant
model
dolabelladienetriol
inhibit
viral
replic
dosedepend
manner
concentr
without
loss
viabil
tissu
author
conclud
compound
great
potenti
possibl
microbicid
compound
also
theoret
analyz
inhibitor
wildtyp
mutant
revers
transcriptas
firstli
structureact
relationship
studi
reveal
low
dipol
moment
high
homo
highest
occupi
molecular
orbit
lumo
lowest
unoccupi
molecular
orbit
gap
valu
relat
antivir
activ
secondli
molecular
dock
studi
rt
wildtyp
mutant
show
seahorselik
conform
hydrophob
interact
hydrogen
bond
import
residu
bind
pocket
final
author
suggest
new
deriv
aromat
moieti
doubl
bond
improv
biolog
activ
although
dolabellan
diterpen
brown
alga
dictyota
spp
show
strong
activ
confirm
dolabellan
diterpen
isol
octocor
therefor
chemic
transform
conduct
improv
potenc
main
dolabellan
r
e
e
trien
caribbean
octocor
eunicea
laciniata
oxygen
dolabellan
deriv
figur
obtain
epoxid
epoxid
open
allyl
oxid
ketodolbellatrien
shown
significantli
improv
antivir
activ
low
cytotox
cell
make
promis
antivir
compound
phlorotannin
tannin
deriv
made
sever
phloroglucinol
unit
link
differ
way
phlorotannin
contain
phenyl
linkag
fucol
ether
linkag
fuhalol
phlorethol
phenyl
ether
linkag
fucophloroethol
dibenzodioxin
linkag
eckol
far
seri
phlorotannin
identifi
potent
antihiv
activ
exampl
marin
brown
alga
ecklonia
cava
shown
enhanc
inhibitori
effect
karadeniz
et
al
report
figur
anoth
phlorotannin
deriv
isol
brown
alga
could
use
drug
candid
develop
new
gener
antihiv
therapeut
agent
compound
show
inhibitori
activ
noncytotox
concentr
precis
result
indic
inhibit
cytopath
effect
includ
induc
syncytia
format
lytic
effect
viral
antigen
product
furthermor
inhibit
entri
rt
enzym
inhibit
ratio
concentr
recent
first
time
xanthon
dimer
identifi
potenti
agent
xanthon
secondari
metabolit
higher
plant
famili
fungi
lichen
although
structur
relat
flavonoid
xanthon
frequent
encount
natur
penicillixanthon
pxa
figur
natur
xanthon
dimer
isol
jellyfishderiv
fungu
aspergillu
fumig
fourteen
natur
product
howev
penicillixanthon
show
inhibitori
activ
hiv
infect
marinederiv
pxa
display
potent
activ
respect
molecular
dock
studi
confirm
pxa
might
bind
either
prevent
hiv
entri
target
cell
therefor
pxa
dualcoreceptor
antagonist
may
seen
new
potenti
lead
product
type
develop
antihiv
therapeut
haart
therapi
caus
sever
side
effect
eg
insulin
resist
lipoatrophi
dyslipidemia
abnorm
fat
distribut
therefor
find
adequ
diet
supplement
lower
neg
effect
haart
combin
therapi
desir
fish
oil
contain
polyunsatur
fatti
acid
pufa
eicosapentaeno
epa
figur
docosahexaeno
dha
figur
acid
may
benefici
effect
hivinfect
patient
shown
addit
fish
oil
diet
hivinfect
individu
receiv
usual
antiretrovir
therapi
significantli
lower
serum
triglycerid
level
highli
relev
know
hiv
dyslipidemia
seriou
problem
relat
increas
frequenc
cardiovascular
diseas
recent
et
al
analyz
influenc
dha
locomotor
activ
ethanoltr
transgen
rat
preval
alcohol
use
alcohol
abus
infect
individu
much
higher
numer
ethanol
viral
protein
synergist
effect
inflamm
central
nervou
system
hiv
remain
bodi
latent
form
haart
therapi
induc
neuroinflamm
dha
deplet
found
associ
variou
neurolog
abnorm
administr
neuroprotect
effect
dha
taken
daili
could
revers
effect
ethanol
neg
effect
locomotor
activ
presenc
hiv
viral
protein
vivo
studi
use
realtim
quantit
pcr
show
addit
dha
reduc
elev
level
increas
express
striatum
prove
potenti
fish
oil
constitu
adjuv
hiv
patient
treatment
help
lower
interact
effect
ethanol
consumpt
hiv
infect
resorcycl
acid
lacton
name
radicicol
figur
pochonin
b
figur
c
figur
isol
h
fuscoatra
exhibit
reactiv
effici
latent
rel
saha
subeoylanilid
hydroxam
acid
vorinostat
hdac
inhibitor
reactiv
strategi
inde
promis
strategi
expung
infect
reactiv
latent
viral
load
mainli
tcell
quickli
rebound
antivir
treatment
interrupt
note
activ
compound
contain
michael
acceptor
function
pkcindepend
mechan
reactiv
latent
remain
elucid
team
research
led
zhao
isol
new
isoprenyl
cyclohexanol
spongeassoci
fungu
truncatella
angustata
name
truncateol
ov
vitro
test
show
truncateol
p
figur
analogu
bear
alkynyl
group
side
chain
exhibit
signific
inhibit
toward
viru
valu
respect
compound
could
consid
new
antihiv
lead
compound
due
lower
cytotox
comparison
posit
control
efavirenz
marin
organ
acknowledg
preciou
sourc
bioactiv
compound
may
provid
novel
antihiv
structur
lead
structur
structur
optim
larg
amount
evid
scientif
research
confirm
high
biolog
potenti
compound
treat
seriou
diseas
includ
infect
one
marinederiv
bioactiv
compound
discov
much
earlier
emerg
novel
properti
potenti
applic
decad
two
isol
structur
elucid
compound
marin
organ
easi
task
still
carri
challeng
identif
compound
daunt
task
especi
regard
complex
structur
motif
may
present
singl
marin
extract
taxonom
knowledg
still
insuffici
enabl
unambigu
speci
classif
result
fals
predict
chemic
constitu
hamper
structur
analysi
furthermor
tempor
lag
discoveri
chemic
character
associ
pharmacolog
activ
quit
common
major
marin
metabolit
usual
test
anticanc
activ
wherea
antihiv
possibl
biolog
effect
neglect
mostli
perform
due
lack
fund
target
assay
vivo
analys
similarli
perform
potenti
candid
translat
clinic
trial
remain
limit
thu
financi
gap
certainli
relev
factor
contribut
slow
drug
develop
process
area
particular
develop
antihiv
compound
act
mechan
differ
exist
antivir
requir
welldesign
focus
approach
studi
mode
action
librari
creat
specif
defin
crude
extract
correspond
simplifi
fraction
well
pure
compound
wellbalanc
natur
product
discoveri
program
addit
exist
public
scientist
tri
modifi
known
compound
marin
origin
improv
bioactiv
howev
continu
wit
advanc
deepsea
explor
technolog
sampl
strategi
genom
sequenc
genom
mine
genet
engin
chemoenzymat
synthesi
nanoscal
nmr
structur
determin
develop
optim
suitabl
ferment
strategi
ensur
continu
suppli
uniqu
bioactiv
compound
ocean
therefor
ground
met
broad
intern
effort
base
scientif
collabor
would
reli
wellequip
infrastructur
human
resourc
prerequisit
full
advanc
field
develop
new
drug
candid
pharmaceut
market
futur
